Platinum Sponsors
AstraZeneca
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to deliver life-changing medicines to patients. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
- www.astrazeneca.com
- Booth number: 5
Eisai
Eisai is dedicated to giving first thought to patients and their families through our human health care (hhc) philosophy. Our dedication to patients drives our efforts to innovate oncology medicines. Our mission is to significantly contribute to society in an ethical, compliant and sustainable way by embodying our hhc philosophy. Eisai is a platinum sponsor of the ESMO Gynae Congress 2023.
EMEA-ONC-22-00120| October 2022
- www.eisai.eu
- Booth number: 6
GSK
GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, oncology cell and gene cell therapy, tumour cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cell therapy, either alone or in combination.
- www.gsk.com
- Booth number: 1
Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development.
- www.regeneron.com
- Booth number: 2
Seagen
Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors.
- www.seagen.com
- Booth number: 3
Gold Sponsor
MSD
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.
- www.msd.com
- Booth number: 7
Silver Sponsor
Alkermes
Headquartered in Dublin, Ireland, Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products for addiction, schizophrenia, and bipolar, and a pipeline of product candidates in development for neurodegenerative disorders and cancer.
- www.alkermes.com
- Booth number: 8
Bronze Sponsors
ImmunoGen
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Mersana Therapeutics
Mersana is a clinical-stage biopharmaceutical company using its proprietary ADC platforms to develop novel ADCs. Mersana’s lead candidate upifitamab rilsodotin (UpRi) is a NaPi2b-targeting ADC being studied in ovarian cancer. Earlier stage candidates include XMT-1660, a B7-H4 directed Dolasynthen ADC, and XMT-2056, a STING agonist Immunosynthen ADC; both are being investigated in a range of solid tumors.
- www.mersana.com
- Booth number: 9
Exhibitor
SeqOne Genomics
SeqOne Genomics is a french startup, founded in 2017. The company develops state-of-the-art genomics analysis tools for clinical applications in the fields of cancer and rare diseases. Its flagship product, SeqOne | Platform is a cloud-based end-to-end solution that dramatically reduces turnaround time and cost required to deliver accurate analyses, for use in mainstream medicine.
- www.seqone.com
- Booth number: 10
Educational Grant
MSD
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.
